Translational cancer research最新文献

{"title":"Clinical immunotherapeutic significance of <i>RAS</i> gene mutations in melanoma.","authors":"Yixin Xu, Xueying Wang, Yulei Guo, Danyu Qian, Qinghua Wang, Zhenpeng Li","doi":"10.21037/tcr-2025-32","DOIUrl":"10.21037/tcr-2025-32","url":null,"abstract":"<p><strong>Background: </strong>The main members of the <i>RAS</i> family, <i>NRAS</i>, <i>KRAS</i>, and <i>HRAS</i>, encode proteins that have a pivotal cytoplasmic role in cells. When <i>RAS</i> genes are mutated, cells grow uncontrollably. In this work, we aimed to investigate the immune checkpoint inhibitor (ICI) implications of <i>RAS</i> mutations in melanoma.</p><p><strong>Methods: </strong>Somatic mutational profiles of a total of 631 melanoma patients derived from previously published eight studies, along with their corresponding ICI treatment information were utilized. We explored the prognostic capacity of <i>NRAS</i>, <i>KRAS</i>, and <i>HRAS</i> mutations in ICI in total patients treated with ICI and in different clinical situations (e.g., type of treatment, age, and gender).</p><p><strong>Results: </strong>Among the three <i>RAS</i> gene mutations, we observed that patients with <i>NRAS</i> mutations were associated with their worst prognosis with ICI treatment [hazard ratio (HR): 1.38; 95% confidence interval (CI): 1.08-1.78; P=0.01]. Further analyses indicated that in patients with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) treatment and combined treatment, the associations between <i>NRAS</i> mutations and ICI resistance were also found (both HR >1, P<0.01). Stratification analyses revealed that the inferior immunotherapeutic survival was also observed in the <i>NRAS</i> mutated groups under the clinical settings of age >60 years and male patients (both P<0.05). Immunological investigation demonstrated that a poorer immune microenvironment was enriched in patients with <i>NRAS</i> mutations.</p><p><strong>Conclusions: </strong>We discovered that <i>NRAS</i> mutations are predictive of the inferior tumor immunogenicity and ICI treatment resistance in melanoma, which might provide a potential indicator for evaluating the immunotherapeutic efficacy.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 8","pages":"4679-4690"},"PeriodicalIF":1.7,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: MicroRNA-494 represses osteosarcoma development by modulating ASK-1 related apoptosis complexes.","authors":"Gan Gao, Yuekui Jian","doi":"10.21037/tcr-2025b-12","DOIUrl":"10.21037/tcr-2025b-12","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.21037/tcr-19-2195.].</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 8","pages":"5177"},"PeriodicalIF":1.7,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid biopsy for the detection of non-viral head and neck squamous cell carcinoma.","authors":"Yukinori Takenaka, Masashi Mori, Hidenori Inohara","doi":"10.21037/tcr-2025-260","DOIUrl":"10.21037/tcr-2025-260","url":null,"abstract":"","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 8","pages":"4482-4485"},"PeriodicalIF":1.7,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid differentiation score-related genes and prognostic model for thyroid cancer.","authors":"Shang Lin, Di Chen, Chen-Wei Pan, Xiang-Chou Yang","doi":"10.21037/tcr-2025-460","DOIUrl":"10.21037/tcr-2025-460","url":null,"abstract":"<p><strong>Background: </strong>Thyroid differentiation score (TDS) reflects the differentiation degree of thyroid cancer (THCA). This study aimed to construct a TDS-related prognostic risk model for THCA and explore the potential biomarkers.</p><p><strong>Methods: </strong>Using The Cancer Genome Atlas (TCGA)-THCA dataset, overlapping differentially expressed genes (DEGs) between THCA-DEGs and TDS-DEGs were identified for functional enrichment analyses to determine their biological functions. Least absolute shrinkage and selection operator (Lasso) and Cox regression analyses were applied to construct a prognostic model. The model's predictive performance was validated through Kaplan-Meier curves, receiver operating characteristic curves, and decision curve analyses. Gene set enrichment analysis (GSEA) was performed to explore the functional pathways. Single-cell RNA sequencing analysis was performed to further explore the role of risk genes.</p><p><strong>Results: </strong>A four-gene risk model, including ATPase secretory pathway Ca²⁺ transporting 2 (<i>ATP2C2</i>), mast cell expressed membrane protein 1 (<i>MCEMP1</i>), FAM111 trypsin-like peptidase B (FAM111B), and uronyl 2-sulfotransferase (<i>UST</i>), was established, with significant predictive value for overall survival. High expression of <i>ATP2C2</i> and <i>MCEMP1</i> correlated with poorer prognosis, while <i>FAM111B</i> and <i>UST</i> were protective factors. GSEA revealed the involvement of apoptosis and p53 signaling pathways with four risk genes. Additionally, <i>UST</i> was linked to p53 signaling pathways in CD4⁺ memory cells, suggesting its critical role in THCA progression.</p><p><strong>Conclusions: </strong>The TDS-related gene risk model demonstrates strong prognostic utility in THCA. UST may inhibit the p53 signaling pathway to activate CD4⁺ memory cells in THCA, highlighting its potential as a therapeutic target.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 8","pages":"4662-4678"},"PeriodicalIF":1.7,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Untargeted metabolomics integrated with SHAP analysis identifies novel biomarkers of oxaliplatin induced peripheral neurotoxicity in gastric cancer.","authors":"Yujiao Hua, Xinlei Liu, Juan Lv, Yan Zhang, Yongjuan Ding, Jinghua Chen","doi":"10.21037/tcr-2025-240","DOIUrl":"10.21037/tcr-2025-240","url":null,"abstract":"<p><strong>Background: </strong>Oxaliplatin-induced peripheral neuropathy (OIPN) is an important adverse reaction in patients with gastric cancer treated with oxaliplatin, but there is no objective biomarkers for changes in OIPN in patients after multiple rounds of chemotherapy. This research aimed to identify serum metabolic biomarkers using longitudinal untargeted metabolomics for early detection of OIPN progression in gastric cancer patients receiving repeated chemotherapy.</p><p><strong>Methods: </strong>Eighty-four serum samples of the same gastric cancer patient (n=42) before and after receiving oxaliplatin chemotherapy twice were collected. The metabolic profiles of serum samples were acquired using an untargeted metabolomics approach based on ultra-high-performance liquid chromatography-Q-Exactive Orbitrap tandem mass spectrometry (UHPLC-Q-Exactive Orbitrap-MS/MS). Multivariate statistical analysis, receiver operating characteristic (ROC) curve analysis, SHapley Additive exPlanations (SHAP) analysis, and pathway enrichment analysis were used to identify potential biomarkers and metabolic pathways.</p><p><strong>Results: </strong>A total of 16 differentially expressed metabolites (DEMs) were screened in discovery set, which belonged to amino acids and derivatives, lipids and derivatives, organic acids and derivatives, and others, mainly involved in amino acid metabolism, lipid metabolism, and nervous system metabolism. Four DEMs (including norepinephrine, 9,10-DHOME, 5-hydroxyindoleacetic acid, and procollagen 5-hydroxy-lysine) showed certain predictive ability for OIPN in the same gastric cancer patient before and after receiving oxaliplatin chemotherapy twice. Thirty-three DEMs were discovered in validation set, notably, norepinephrine emerged as a metabolite exhibiting consistent and notable statistical differences in both the discovery and validation sets.</p><p><strong>Conclusions: </strong>These findings demonstrate the alterations of serum metabolic profiles in patients before and after receiving oxaliplatin chemotherapy, which may deliver valuable biomarkers for early identification and outcome prediction of OIPN progression.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 8","pages":"4621-4637"},"PeriodicalIF":1.7,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the efficacy of combined modality therapy versus chemotherapy alone in unresectable primary pulmonary diffuse large b-cell lymphoma: a retrospective cohort study.","authors":"Yuchen Liu, Ruonan An, Ping Cheng, Guofeng Sun","doi":"10.21037/tcr-2025-34","DOIUrl":"10.21037/tcr-2025-34","url":null,"abstract":"<p><strong>Background: </strong>Primary pulmonary diffuse large B-cell lymphoma (PP-DLBCL) is a rare and aggressive extranodal lymphoma, with no consensus on optimal treatment strategies. For unresectable cases, current evidence is insufficient to determine whether the addition of radiotherapy (RT) to chemotherapy (CT) provides a survival benefit. To address this gap, we used data from the Surveillance, Epidemiology, and End Results (SEER) database to compare survival outcomes between combined modality therapy (CMT) and CT alone in patients with unresectable PP-DLBCL.</p><p><strong>Methods: </strong>Data on patients with unresectable PP-DLBCL were extracted from the SEER database of the National Cancer Institute, using SEER*Stat software (v8.4.3). Propensity score matching (PSM) was applied to adjusted confounding factors. Overall survival (OS) and cancer-specific survival (CSS) were estimated using Kaplan-Meier methods, and differences between groups were assessed using the log-rank test. Hazard ratios (HRs) were calculated using Cox proportional hazards models.</p><p><strong>Results: </strong>A total of 880 patients with unresectable PP-DLBCL diagnosed between 2000 and 2021 met the inclusion criteria and the median follow-up were 87 months. The estimated 5-year OS rate was 65.4% [95% confidence interval (CI): 60.1-70.7%]. Of these patients, 719 received CT alone and 161 received CMT. Significant differences in primary tumor site and laterality were observed between the two groups (P<0.001). The analysis revealed a significant association between CMT and improved OS (HR, 0.77; 95% CI: 0.59-0.99), and this association remained consistent in the sensitivity analysis using PSM. Additionally, univariate and multivariate Cox regressions indicated that sex, age and Ann Arbor stage were independent prognosis factors of OS.</p><p><strong>Conclusions: </strong>Our findings suggest that CMT may improve survival in patients with unresectable PP-DLBCL. Moreover, the prognostic factors identified in this study may help in identifying high-risk patients. Our findings provide new evidence to support the clinical management of this rare patient population.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 8","pages":"4574-4585"},"PeriodicalIF":1.7,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing natural killer cell-related genes for prognostic and therapeutic advances in lung adenocarcinoma: a predictive model for survival and immunotherapy outcomes.","authors":"Minqi Zhu, Likang Wang, Fang Chen","doi":"10.21037/tcr-2025-380","DOIUrl":"10.21037/tcr-2025-380","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Lung adenocarcinoma (LUAD), the most common subtype of non-small cell lung cancer (NSCLC), is characterized by high mortality rates and complex immune evasion mechanisms. Natural killer (NK) cells play a crucial role in tumor immune surveillance, with their activity regulated by specific genes. Recently, biomarkers derived from NK cell-related genes have garnered significant attention for their potential in predicting cancer prognosis. This study aimed to evaluate the clinical utility of a prognostic model based on NK cell-related genes in patients with LUAD.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In this study, gene expression data and clinical information from LUAD patients were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, and differentially expressed genes associated with natural killer cells (DENKCRGs) were identified. A prognostic risk score model was developed using least absolute shrinkage and selection operator (LASSO) regression and Cox regression analysis. The model's performance was subsequently validated through Kaplan-Meier survival curves, receiver operating characteristic (ROC) curves, enrichment analysis, and immune infiltration analysis. Additionally, its predictive capacity for immune therapy response and drug sensitivity was evaluated.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 493 LUAD patient datasets were retrieved from TCGA, 857 from the GEO database, and 244 NK cell-related genes were identified based on prior studies. The filtered data were then partitioned into training and testing sets. Through LASSO regression and Cox regression analysis, eight genes (&lt;i&gt;PAK1&lt;/i&gt;, &lt;i&gt;PLCG2&lt;/i&gt;, &lt;i&gt;SHC3&lt;/i&gt;, &lt;i&gt;SHC1&lt;/i&gt;, &lt;i&gt;TOX&lt;/i&gt;, &lt;i&gt;ARRB2&lt;/i&gt;, &lt;i&gt;SERPINB4&lt;/i&gt;, and &lt;i&gt;NLRC4&lt;/i&gt;) were identified as significantly associated with prognosis. A prognostic model based on these genes was developed, categorizing patients into high-risk and low-risk groups. Strong predictive performance was observed in the training set, testing set, and GEO dataset. Immune infiltration analysis revealed notable differences in immune cell distribution and immune response intensity between the high-risk and low-risk groups, with low-risk patients demonstrating greater responsiveness to immunotherapy. Furthermore, drug sensitivity analysis indicated that the high-risk group exhibited increased sensitivity to Axitinib, while the low-risk group showed higher responsiveness to drugs such as cisplatin.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The prognostic model developed in this study, based on NK cell-related genes, demonstrates considerable value in assessing the prognosis of LUAD. It not only serves as a predictor of patient survival but also provides a theoretical foundation for personalized immunotherapy and drug selection. Future research should focus on further validating the clinical applicability of this model and exploring its potential in the context of immunotherapy and targeted therapies.","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 8","pages":"4598-4620"},"PeriodicalIF":1.7,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic implication of endoplasmic reticulum stress-related gene signature in lung adenocarcinoma and its effect on tumor immunity.","authors":"Yangyang Xu, Tingting Cai, Jun Xie, Qian He, Chong Li","doi":"10.21037/tcr-2024-2294","DOIUrl":"10.21037/tcr-2024-2294","url":null,"abstract":"<p><strong>Background: </strong>Endoplasmic reticulum stress (ERS) can affect the efficacy of anti-tumor therapy (chemotherapy, targeted therapy and immunotherapy) by regulating tumor immune microenvironment. This study aims to develop a prognostic prediction model based on the expression profiles of ERS-related genes to guide the treatment of lung adenocarcinoma (LUAD).</p><p><strong>Methods: </strong>The 16-gene prognostic signature was established to predict the prognosis of LUAD patients using The Cancer Genome Atlas (TCGA) database. We applied consensus clustering and found that LUAD could be divided into two groups based on the expression of <i>PIK3CG</i> and <i>DMD</i>. We performed gene set enrichment analysis (GSEA) to identify functional differences, and used ESTIMATE, CIBERSORT, and single-sample GSEA (ssGSEA) to assess immune infiltration. In addition, we compared the expression of immunomodulatory targets between the two clusters.</p><p><strong>Results: </strong>We successfully constructed a 16-gene prognostic signature and a nomogram to help individualize outcome prediction in LUAD. The ERS risk signature is an independent prognostic factor for LUAD patients, and a higher score indicates a poorer prognosis. Through consensus clustering based on the expression of <i>PIK3CG</i> and <i>DMD</i>, LUAD patients can be divided into two groups. Cluster 1, with high <i>PIK3CG</i> and low <i>DMD</i> expression, shows stronger immune infiltration and higher expression of immunomodulatory targets, suggesting a better response to immunotherapy compared to cluster 2. These findings were further validated in an independent cohort (GSE68465), confirming the reproducibility of the immune landscape distinction between the clusters.</p><p><strong>Conclusions: </strong>The ERS-associated gene signature can effectively predict the prognosis of LUAD patients. In addition, we found that <i>PIK3CG</i> and <i>DMD</i> play a certain role in tumor immunity and may be potential therapeutic targets.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 8","pages":"4851-4866"},"PeriodicalIF":1.7,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Facilitation of natural killer T-cell cytotoxic activity in uterine sarcoma via the <i>CKS2-PI3K-AKT-MICA</i> axis.","authors":"Yali Du, Ting Lan, Mengyuan Liu, Weiyan Wu, Jinqi Ma","doi":"10.21037/tcr-2025-1405","DOIUrl":"10.21037/tcr-2025-1405","url":null,"abstract":"<p><strong>Background: </strong>Uterine sarcoma constitutes approximately 3-7% of all uterine cancers, with adenosarcoma and leiomyosarcoma being the major subtypes. This neoplasm is characterized by poor clinical outcomes, with frequent recurrence and metastasis, underscoring the urgent need for early detection strategies. Cyclin-dependent kinase regulatory subunit 2 (<i>CKS2</i>) is markedly overexpressed in uterine sarcoma. Preliminary data suggest that <i>CKS2</i> overexpression correlates with advanced tumor staging, yet its mechanistic link to immune evasion via natural killer T (NKT)-cell regulation remains unexplored. This study aimed to explore how <i>CKS2</i> regulates the immune response in uterine sarcoma.</p><p><strong>Methods: </strong>Through the integration of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, a systematic analysis was conducted on the correlation between <i>CKS2</i> expression levels, tumor prognostic staging, and immune cell infiltration. Stable <i>CKS2</i>-knockdown cell lines were constructed, and the expression changes of <i>CKS2</i> were detected via quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and Western blot techniques. Through colony formation assays, TUNEL staining, invasion and migration assays, and Western blot analysis, the mechanism related to the regulatory effect of <i>CKS2</i> on the malignant progression of uterine sarcoma cells was clarified in depth. Additionally, the specific mechanism by which <i>CKS2</i> regulates NKT cell activity was verified at the tissue level via multiplex immunofluorescence.</p><p><strong>Results: </strong>In uterine sarcoma, <i>CKS2</i> expression was found to be significantly upregulated and closely associated with poor prognosis, advanced tumor stage, and a distinct negative correlation with NKT cell activity. <i>In vitro</i> experiments indicated that knockdown of <i>CKS2</i> significantly inhibited the proliferation, migration, and invasion of sarcoma cells and promoted apoptosis. Mechanistically, <i>CKS2</i> activated the <i>PI3K/AKT</i> signaling, reduced major histocompatibility complex (MHC) class I chain-related protein A (<i>MICA</i>) expression, and inhibited NKT cell activity, resulting in immune escape, which was effectively mitigated by <i>PI3K</i> inhibitors.</p><p><strong>Conclusions: </strong>The findings suggest that <i>CKS2</i> can serve as a valuable biomarker and an effective target for the prevention and screening of uterine sarcoma and can modify the antitumor immune response in uterine sarcoma.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 8","pages":"5045-5058"},"PeriodicalIF":1.7,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel prognostic model based on endoplasmic reticulum stress-associated E3 ligases and deubiquitinating enzymes in hepatocellular carcinoma.","authors":"Caixia Zhong, Yurui Liu, Kaishun Hu, Dong Yin","doi":"10.21037/tcr-2024-2403","DOIUrl":"10.21037/tcr-2024-2403","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is classified as one of the leading malignant neoplasms worldwide, exhibiting a rising trend in its global incidence. The imperative for the development of innovative diagnostic and prognostic biomarkers is critical for improving the therapeutic and management strategies for patients with HCC. This study was undertaken to identify endoplasmic reticulum stress-associated E3 ubiquitin ligases and deubiquitinating enzymes (ERS-E3s/DUBs) and to construct a prognostic risk model for HCC.</p><p><strong>Methods: </strong>The transcriptomic and clinical data were obtained from The Cancer Genome Atlas (TCGA) database. By analyzing the transcriptomic data treated with endoplasmic reticulum stress inducers, we identified differentially expressed E3 ubiquitin ligases (E3s) and deubiquitinating enzymes (DUBs). A prognostic risk model based on ERS-E3s/DUBs was developed using least absolute shrinkage and selection operator (LASSO) and Cox regression analyses. Utilizing the Akaike Information Criterion for computation, we ascertained the most appropriate threshold for stratifying patients into distinct categories of high-risk and low-risk cohorts. Subsequently, we predicted and analyzed the survival prognosis and Gene Ontology analyses of patients in high- and low-risk groups.</p><p><strong>Results: </strong>In this study, we systematically recognized 23 ERS-E3s/DUBs and developed a liver cancer prognostic risk model founded on nine ERS-E3s/DUBs. Furthermore, we formulated a new nomogram that combines risk characteristics and clinical pathological features, which provides good predictive performance for the clinical prognosis of HCC patients.</p><p><strong>Conclusions: </strong>We identified ERS-E3s/DUBs and constructed a prognostic risk model for HCC.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 8","pages":"4539-4548"},"PeriodicalIF":1.7,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}